Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0761-8425(07)91158-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.
Hum Vaccin Immunother
December 2025
Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).
View Article and Find Full Text PDFBackground: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.
Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics.
Increased rate of multidrug-resistant gram-negative bacterial infections in hospitalized immunocompromised pediatric patients.
Front Cell Infect Microbiol
January 2025
Center for Infectious Diseases Research (CIDR) and WHO Collaborating Center for Reference and Research on Bacterial Pathogens, American University of Beirut, Beirut, Lebanon.
Introduction: Multidrug resistant Gram-negative bacterial infections are considered a major public health threat. Immunocompromised pediatric patients are at a great risk of severe or overwhelming infections. The aim of this study was to describe the frequency of infections with multidrug resistant (MDR) Gram-negative bacteria (GNB) in immunocompromised pediatric patients and to determine the risk factors.
View Article and Find Full Text PDFPoint prevalence survey of antibiotics in a pediatric tertiary hospital in the Republic of Panama.
Rev Panam Salud Publica
January 2025
Infectious Diseases Unit Hospital Carlos G. Durand Buenos Aires Argentina Infectious Diseases Unit, Hospital Carlos G. Durand, Buenos Aires, Argentina.
Objective: To conduct a point prevalence survey (PPS) of antibiotic use in the main pediatric tertiary-level hospital in Panama City to establish antibiotic prevalence and identify key areas for addressing antimicrobial resistance.
Methods: This point prevalence survey (PPS) conducted in a tertiary-level hospital in Panama followed the Pan American Health Organization's adaptation of the methodology proposed by the World Health Organization for PPSs on antibiotic use. Information obtained included patients' demographic characteristics, antimicrobial prescriptions, indication for antimicrobial use, and prescription's adherence to guidelines.
Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity.
Front Immunol
January 2025
Inflammation and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Background: Factors leading to severe COVID-19 remain partially known. New biomarkers predicting COVID-19 severity that are also causally involved in disease pathogenesis could improve patient management and contribute to the development of innovative therapies. Autophagy, a cytosolic structure degradation pathway is involved in the maintenance of cellular homeostasis, degradation of intracellular pathogens and generation of energy for immune responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!